Post-Prandial Effects of Dairy Products in Middle-Aged Me

Recruiting

• Conditions: Sarcopenia; Musculoskeletal - Normal musculoskeletal and cartilage development and function

• Registration Number: ACTRN12613001100785
• Lead Sponsor: Fonterra Co-operative Group Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-10-02
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 48

Inclusion Criteria

Healthy
Male
45-60 yrs
BMI (18-30kg/m2)
Sedentary to moderately active

Exclusion Criteria

Diabetes or cardiovascular disease risk or current pharmaceutical therapy.
Other medical conditions impacting on digestion, including diseases of the gastrointestinal tract, allergy to dairy protein and history (or medical management) of mental illness.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Muscle protein synthesis determined based on a primed constant infusion of L-[ring-(13)C(6)]phenylalanine and L-[ring-(2)H(2)]tyrosine, in conjunction with repeated muscle biopsies.[At 90 min to 210 min after ingestion.];Muscle metabolism biomarkers including microRNAs assessed by real-time qPCR in plasma and skeletal muscle.[At baseline, 15, 30, 45, 60, 75, 90, 120, 150, 180, 210 min after ingestion]

Secondary Outcome Measures

Name	Time	Method
Plasma amino acids assessed by HPLC.[At baseline, 15, 30, 45, 60, 75, 90, 120, 150, 180, 210 min after ingestion]